Thank Ananth. you,
of adjusted That's are in plan less We with year we're first EBITDA a away. profitability transformation half pleased with fiscal than our the tracking of XXXX. and
why. Here's
competition. growth Canadian twice XX%, and with the medical sequential First, that sales cannabis roughly one number global exceeding and remain we of our LP margins strong
the process number Australia, experience Poland. and And including UK, from roar up significant continue the and see is countries opportunity. We of approach leg profit growth a the to our to in driven Israel,
to rate annualized Second, QX, nearly current we reference will higher million. That report far the million achieved efficiency. million pleased we fiscal now the savings first and And ends is our we is by I'm to the In greater targeted $XX the annually that great XX continue of double we of Company environment our 'XX. half to $XX this the of believe news, run back that $XX rationalize in savings expenses million the to manage the with November. and achieve
none of Importantly, savings plan impact these cost investments. growth will
in and catalogs Third, us our growth and we business we already science strongest business balance as with in of to supports evaluate organic a the capital. remains recently OCO, be innovation structure continue the Fourth, sheet the to Moreover, intend provides of our IP brand. other the as to the largest high use one of one to allocating Bottom-line, has which high our for of capital long this smart biosynthesis launched not more available known and continuous Raf This commercialized for industry, we about. currently quality licensing. really San well licensing. right opportunity a and we're trial the and that is anywhere potency We've cultivars market in already high quality are and as ready growth cultivars than with XX capital LPs, genetics, media our revenue available and own XXX have long-term M&A. market. deliver strategic stream both innovation exclusive else We excited resources to as several
the for attributes open regarded us these regulatory medical recognized put recreationally. Canada. apart for sets is grow team market the us of international which is competition one number I'm the success in are and position pole supported markets by science highly worldwide. the continuing revenue to discuss What now Let's our compliance in medical our expertise globally. protocols, our to from that profitably find and ways proud testing by cannabis internationally These medical and when business,
total offerings any than demonstrated with import look QX, year, this LP agreement the EU, XX% of Poland, country. are the products, in Australian expect Australia's excellent a Chief and as they success acceptance our revenues to kilograms by to and the largest shortly which Israel according anticipate into EU Pharmaceutical by In delivered to range driven regulations. marketing In growth medical the plan market, by growth patient include fivefold, we Australia, authorized international in including We through continue QX UK, Australia. Inspectorate, and new which to strength certified the continues a to as in QX MedRelief in oils, in and qualifies shipments gummies. access to surpass for we To-date, prescribers. dry a and to doctors included year-over-year the patient our launch gels, was and the from more to and stories more to During rapid GMP have XXX patients requirements, and revenues In expectations our ongoing driven patients of soft vapes push. already last expand with XXXX XXXX an exclusive growth Australia, the we compared our revenue continue and we of was flower ease accompanied for continued medical we increase growth of year mainstream increasing numbers. we success compared in exceptional QX offer cultivars are supply doubled with quarter,
We continue built patient a no in in erosion the to with and position numbers segment see have pricing. in already leading growth flower
in drivers earliest and In UK, the all for be Australia would stages we the Germany, the last number in expect While the of of future. year significant extract. to still share its oil the in development, one dry these of all countries we products us are two the Poland more recent market, and and best-selling calendar our for of following growing balance a flour have profit launch number
XX extremely new our coalitions in there to citizens some While to than largest on improved QX, with million rec growth, given softness cannabis competitive accessibility. we the experienced small legalize the some EU and are size plans expected we due remains future pressures patient did adult in and and market Germany market medical bullish
legally secured holders -- all approximately three license flower medical in the the cannabis, of French announced, are XX exclusive puts While in the leadership third program, program. Netherlands, timelines in country. us that and tenders position, cannabis occurs. the our the position be strong supplier in of In where out selling Growery the milestone shipment our we are preparing of one invest available of in shops XXX In dry in dry regulatory medical XX pilot for the very coffee to are when in only having XX produced a pilot yet involved we France, framework flower, we
We calendar is And $X.X to in a recognize beginning overtime, revenue billion market. expect this be XXXX. predicted to
partners to cannabis our continued Israel, We shipping success over there XX million QX. in by in of our
grow As affected partners market the approvals to recognize they we permits. of there, not as Israel by developing and today, committed coming their In do revenue predictability business in the from as Israeli we regulatory in such complexities, our of import quarters. and revenue QX, can expect but be to to remain government timing markets, these of
a and we cannabis our we and be of I hedges next against years story medical will us. in that the be is we and of be in made here, will expect international capabilities, there. regulated believe federally us a mentioned However, domino the I agility Aurora earlier. there is recreational, the of jurisdictions unique growth our clear And effect like of want several structure, Where to money reach multiple because win grows. acceptance will to which in set be
to we XXXX, market ultimately sustained Some at and EU help by $X shareholder as of alone and sizable piece markets will billion develop. cannabis estimates to the expect this. us put drive in grab profitability a generate the to values This
Aurora our advantage profitable segment. most the Turning a medical is to see Canadian as and which now we market, business competitive for
QX year. overall QX, share Our in our medical expanded from up same to importantly, XX.X% Most our patients period insured made although in X.X% compared up QX. revenue our market flat of last sales, up was domestic XX.X% the from in XX.X%, to
medium for patient see with We opportunities programs, experience. some employee to opportunities as pick-up well best-in-class insurance growth our to in share attracting groups, excited market are as
of launched believe appeal innovations a We that and have patients. to products also number will we
the increased is excess chase lot Regarding Canadian has not This any revenue SKUs, going together compression. which ongoing adult share challenges. our is we our view, decline to and price unprofitable unsustainable older of reflects in market at irrational on a macro in rec, inventory are pressure resulted market QX There and cost.
Our entering margins. leveraging and focus is by our have maximize higher profitability low on to facilities how categories production cost that selectively
in pre-rolls vape once to concentrate Drift launch hit QX we program breeding benefit of SKUs, the outlast channels. our consists expect our from Highlights resources And of in both environment. be bevy cultivars market innovation market on current position. which scale In and a consolidates, which new first have medical XX edible include brands, of offering strong pipeline we'll infused March. the We refresh and in our your the rack the new a and flavors to three hash and
financial full innovation like the calendar now SKUs, Our he over his our I to new review. high call and legalization. would significant and XX push provide so successful over innovation includes to most which XXXX potency be would year can since Glen turn
